Archive: 05/10/2017
PFS up with obinutuzumab-based Tx in follicular lymphoma
(HealthDay)—For patients with follicular lymphoma, obinutuzumab-based immunochemotherapy is associated with longer progression-free survival than rituximab-based therapy, according to a study published online Oct. 4 in ...
Oct 5, 2017